{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:18:06Z","timestamp":1777936686765,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Control of disease-related symptoms is a goal of chemotherapy for patients with locally advanced (LA) unresectable or metastatic gastric\/gastroesophageal junction (mG\/GEJ) adenocarcinoma. This study describes disease-related symptoms and healthcare resource utilization (HRU) in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective review of adult patients with claudin 18.2\u2013positive (CLDN18.2+), human epidermal growth factor receptor 2\u2013negative (HER2\u2212), LA unresectable or mG\/GEJ adenocarcinoma was performed. Outcomes were assessed from the index date (date of diagnosis) through the follow-up end date (earliest of first-line treatment discontinuation, last follow-up visit, death, or 1 year after index date).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Sixty-two patients were included in the analysis (mean age, 61.3 years; 54.8% male; 88.7% White; 67.7% had gastric primary tumors; 75.8% had peritoneal metastases; 98.4% received first-line treatment [mean time from diagnosis to treatment initiation, 37.0 days]). All patients reported \u2a7e1 disease-related symptom (mean = 7.2) at the index date. The most common symptoms at the index date were weight loss (74.2%), abdominal pain\/stomach pain (66.1%), anemia\/weakness (61.3%), poor appetite (56.5%), and epigastric pain (50.0%). Of the 21 patients evaluated at the 6-month follow-up, 95.2% reported \u2a7e1 disease-related symptom. The greatest changes were seen for weight loss (0.0% at 6 months vs 74.2% at the index date), epigastric pain (9.5% vs 50.0%), poor appetite (23.8% vs 56.5%), reflux (4.8% vs 35.5%), early satiety (0.0% vs 29.0%), and abdominal pain\/stomach pain (38.1% vs 66.1%). A mean of 3.4 outpatient visits per patient per month was reported (mean follow-up, 6.5 months), 21.0% of patients had an inpatient admission, and 35.5% had an emergency department visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study demonstrates substantial disease-related symptom burden and high HRU for patients with CLDN18.2+, HER2\u2212, LA unresectable or mG\/GEJ adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795549261430041","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T16:55:20Z","timestamp":1774803320000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2\u2013Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4804-1891","authenticated-orcid":false,"given":"Matheus","family":"Sewastjanow-Silva","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mok","family":"Oh","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Chang","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arijit","family":"Ganguli","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane E","family":"Rogers","sequence":"additional","affiliation":[{"name":"Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca E","family":"Waters","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto Rosa","family":"Vicentini","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-325X","authenticated-orcid":false,"given":"Todor I","family":"Totev","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Q","family":"Wu","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Iwata","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaffer A","family":"Ajani","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12733"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05501-1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13474-9"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27492"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2152\/jmi.68.90"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184400"},{"key":"e_1_3_3_9_2","first-page":"341","article-title":"A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients","volume":"29","author":"Fukahori M","year":"2021","unstructured":"Fukahori M, Shibata M, Hamauchi S, Kasamatsu E, Machii K. A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients. Support Care Cancer. 2021;29:341-348.","journal-title":"Support Care Cancer"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2018.883"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1104447"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05610-x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.04.221"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0977"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.03.457"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111095"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0022"},{"key":"e_1_3_3_21_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Gastric Cancer Version 1.2026. 2025. Accessed December 17 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_3_3_24_2","article-title":"Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma","volume":"8","author":"Waters R","year":"2024","unstructured":"Waters R, Sewastjanow-Silva M, Yamashita K, et al. Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma. JCO Precis Oncol. 2024;8:e2300543.","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655716"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae010"},{"key":"e_1_3_3_27_2","first-page":"53","article-title":"Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma","volume":"32","author":"Wang L","year":"2026","unstructured":"Wang L, Wang A, Valderrama A, et al. Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. J Manag Care Spec Pharm. 2026;32:53-65.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549261430041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795549261430041","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549261430041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:40:38Z","timestamp":1777693238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795549261430041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"alternative-id":["10.1177\/11795549261430041"],"URL":"https:\/\/doi.org\/10.1177\/11795549261430041","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"11795549261430041"}}